2016 American Transplant Congress
Plasma Alemtuzumab Levels Show Great Interpatient Variability, but Are Not Associated with Late Acute Rejection in Simultaneous Pancreas-Kidney Recipients.
Introduction: Alemtuzumab induction followed by a steroid-free, tacrolimus (Tac) and mycophenolate mofetil (MMF) based regimen effectively prevented acute rejection after simultaneous pancreas-kidney transplantation (SPKT). Acute…2016 American Transplant Congress
Reduced CMV Infection Using Single Low-Dose of Rabbit Anti-Thymocyte Globulin in Kidney Transplanted Recipients.
Hospital do Rim - UNIFESP, Sao Paulo, Brazil.
BACKGROUND: Cytomegalovirus (CMV) infection is associated with significant morbidity and mortality after solid organ transplantation and the historic incidence of our institution was 77%. Aiming…2016 American Transplant Congress
Do Powerful Induction Antibodies Increase Post Renal Transplant Infections?
Transplant Institute, Tulane University School of Medicine, New Orleans, LA.
Purpose: Infection is one of the most common and costly complications of solid organ transplantation. Alemtuzemab (AL) is a powerful antibody that significantly reduced rejection…2016 American Transplant Congress
Biopsies for Delayed Graft Function After Alemtuzumab Induction in Kidney Transplantation: The Incidence of Early Rejection After Alemtuzumab Is Very Low but Not Negligible.
IntroductionUK practice advocates transplant biopsy (Bx) at day 7, then weekly in the presence of delayed graft function (DGF) because if missed, early rejection adversely…2016 American Transplant Congress
Quality Assessment and Process Improvement of Thymoglobulin Dosing.
University of Minnesota, Minneapolis.
Thymoglobulin (Thymo) induction is given to prevent early rejection while initiating maintenance immunosuppression. Modification of dosing is common for multiple reasons. Our center recently underwent…2016 American Transplant Congress
Impact of Induction Therapy on Cardiovascular Events in Kidney Transplant Recipients.
1MUHC, Montreal, Canada; 2JHU, Baltimore.
Cardiovascular events (CVE) are one of leading causes of mortality in kidney transplant (KT) recipients and ATG use is reported as a risk factor. We…2016 American Transplant Congress
Surveillance Biopsy Findings with Alemtuzumab (ALZ) Induction in Kidney Transplantation.
The risk of subclinical histological changes in renal allografts with ALZ induction is not well defined. Hence, we performed a retrospective analysis of 527 surveillance…2016 American Transplant Congress
Plasma Cell Frequency in Renal Rejection After Treatment with Alemtuzumab.
Transplantation, The University of Toledo, Toledo, OH.
Background: The highly successful induction drug Alemtuzumab (Campath) is commonly used prior to renal transplant. Yet, it does not completely ablate plasma cell which, in…2016 American Transplant Congress
Long-Term Outcomes of ATG versus IL-2 Receptor Antagonist in Low Risk Kidney Transplant Recipients: Donor Factors.
Controversy exists regarding the optimal choice of induction therapy in low-risk kidney transplant (KT) recipients. Current guidelines specify induction choices in KT based on recipient…2016 American Transplant Congress
Limiting Helper Functions of CD4 T Cells Improves Efficacy of Induction Therapy without Compromising Responses to Third Party Antigens.
Antibody mediated lymphocyte depletion is commonly used in clinical transplantation. However, memory T cells undermine the efficacy of lymphoablative induction therapies in sensitized transplant recipients.…
- « Previous Page
- 1
- …
- 24
- 25
- 26
- 27
- 28
- …
- 31
- Next Page »